Rezolute initiated with an Outperform at Wedbush

Wedbush initiated coverage of Rezolute (RZLT) with an Outperform rating and $12 price target The company’s ongoing Phase 3 study of lead candidate RZ358, an insulin receptor antibody that attenuates downstream signaling for the treatment of congenital hyperinsulinism, should have a high probability of meeting primary endpoint in the second half of 2025, the analyst tells investors in a research note. The firm says positive outcomes from an expanded access program in tumor-induced hyperinsulinism bode well for a Phase 3 study in this patient population that will begin in the first of half of 2025. It projects 2035 U.S. and European Union revenue of $652M “with conservative assumptions.”